Description: Xvivo Perfusion AB (publ), a medical technology company, develops solutions for organ, tissue, and cell preservation and perfusion in connection with transplantation in Sweden, the United States, North America and South America, Europe, the Middle East, Africa, and the Asia Pacific. The company offers XVIVO System (XPS), an integrated off-the-shelf cardiac bypass system that includes various components needed to safely run normothermic ex vivo lung perfusion (EVLP); XPS Disposable Lung Kit that contains disposables and pre-packed products to suit requirement for sterility; and STEEN Solution, a buffered extracellular solution optimally designed to perfuse the isolated donor lung during EVLP. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XVIVO Silicone Tubing Set for rapid flushing of donor lungs during procurement; and XVIVO LS and XVIVO Disposable Lung Set, a device for EVLP. In addition, the company offers XVIVO Organ Chamber, a single-use sterile disposable container intended to be used as a temporary receptacle for isolated lungs in preparation for eventual transplantation into a recipient; and XVIVO Lung Cannula Set, a single-use, sterile disposable product. The company was incorporated in 1998 and is headquartered in Gothenburg, Sweden.
Home Page: www.xvivoperfusion.com
MAessans gata 10
Gothenburg,
412 51
Sweden
Phone:
46 3 17 88 21 50
Officers
Name | Title |
---|---|
Mr. Christoffer Rosenblad | Chief Exec. Officer |
Mr. Kristoffer Nordstrom | CFO & Investor Relations |
Ms. Lena Hagman B.Sc. | Chief Operating Officer |
Dr. Magnus Nilsson Ph.D. | Sr. Advisor |
Ms. Katrin Gisselfalt Ph.D. | Global Quality Assurance & Regulatory Affairs Director |
Mr. Andreas Wallinder M.D., Ph.D. | Chief Medical Officer |
Mr. Johan Holmstrom | Chief Commercial Officer |
Ms. Charlotte Walldal | Global R&D director |
Jaya Tiwari | VP Clinical and Regulatory Affairs |
Mr. Christer de Flon | Mang. |
Exchange: PINK
Country: US
Currency: US Dollar ($)
Forward PE: | 0 |
---|---|
Trailing PE: | 0 |
Price-to-Book MRQ: | 0 |
Price-to-Sales TTM: | 0 |
IPO Date: | |
Fiscal Year End: | December |
Full Time Employees: | 118 |